Insulin pump based expert system

ABSTRACT

An apparatus comprising a pump configured to deliver insulin, an input configured to receive blood glucose data, a user interface, and a controller communicatively coupled to the pump, the input, and the user interface. The controller includes a blood glucose data module to compare the blood glucose data to a target blood glucose level for an insulin pump user. The controller is configured to present a question related to the blood glucose level via the user interface when the blood glucose level is different than the target blood glucose level, receive a response to the question via the user interface, and present a recommended user action based at least in part on the response. Other devices, systems, and methods are disclosed.

RELATED APPLICATION

This application is a continuation of application Ser. No. 13/465,570filed May 7, 2012, which in turn is a division of application Ser. No.11/755,480 filed May 30, 2007, now U.S. Pat. No. 8,221,345 issued Jul.17, 2012, each of which is hereby fully incorporated herein byreference.

TECHNICAL FIELD

The field generally relates to patient insulin management devices and,in particular, but not by way of limitation, to systems, devices andmethods for managing insulin therapy.

BACKGROUND

People who suffer from diabetes require insulin to keep their bloodglucose level as close as possible to normal levels. It is essential forpeople with diabetes to manage their blood glucose level to within anormal range. Complications from diabetes can include heart disease(cardiovascular disease), blindness (retinopathy), nerve damage(neuropathy), and kidney damage (nephropathy). Insulin is a hormone thatreduces the level of blood glucose in the body. Normally, insulin isproduced by beta cells in the pancreas. In non-diabetic people, the betacells release insulin to satisfy two types of insulin needs. The firsttype is a low-level of background insulin that is released throughoutthe day. The second type is a quick release of a higher-level of insulinin response to eating. Insulin therapy replaces or supplements insulinproduced by the pancreas.

Conventional insulin therapy typically involves one or two injections aday. The low number of injections has the disadvantage of allowinglarger variations in a person's insulin levels. Some people withdiabetes manage their blood glucose level with multiple daily injections(MDI). MDI may involve more than three injections a day and four or moreblood glucose tests a day. MDI offers better control than conventionaltherapy. However, insulin injections are inconvenient and require adiabetic person to track the insulin doses, the amount of carbohydrateseaten, and their blood glucose levels among other information criticalto control.

It is important for a diabetic person to be treated with the properamount of insulin. As discussed previously, high blood sugar can lead toserious complications. Conversely, a person with low blood sugar candevelop hypoglycemia. Ideally, insulin therapy mimics the way the bodyworks. An insulin pump is one way to mimic the body's insulinproduction. An insulin pump can provide a background or basal infusionof insulin throughout the day and provide a quick release or bolus ofinsulin when carbohydrates are eaten. If a person develops high bloodsugar, a correction bolus can be delivered by the pump to correct it.While insulin pumps improve convenience and flexibility for a diabeticperson, they can be sophisticated devices. Some insulin pumps can bedifficult to program. Proper use of an insulin pump requires a user togo through a learning curve to properly treat their diabetes using theinsulin pump.

SUMMARY

This document discusses, among other things, devices and methods formanaging insulin therapy. A device example includes a pump configured todeliver insulin, an input configured to receive blood glucose data, auser interface, and a controller communicatively coupled to the pump,the input, and the user interface. The controller includes a bloodglucose data module to compare the blood glucose data to a target bloodglucose level for an insulin pump user. The controller is configured topresent a question related to the blood glucose level via the userinterface when the blood glucose level is different than the targetblood glucose level, receive a response to the question via the userinterface, and present a recommended user action based at least in parton the response.

A method example includes receiving blood glucose data into a devicethat includes an insulin pump, presenting a question related to a bloodglucose level of an insulin pump user when determining, from the bloodglucose data, that the blood glucose level is different from a targetblood glucose level, receiving at least one response to the questioninto the insulin pump device, and presenting a recommended action for auser to take based, at least in part, on the response.

A system example includes a first device and a second device. The firstdevice includes a pump configured to deliver insulin, an input thatincludes a communication port configured to receive blood glucose data,a user interface, and a controller communicatively coupled to the pumpmechanism, the input, and the user interface. The controller includes ablood glucose data module configured to compare the blood glucose datato a target blood glucose level for an insulin pump user. The controlleris configured for presenting a question related to the blood glucoselevel when the blood glucose level is different from a target bloodglucose level, receiving a response to the question via the userinterface, and presenting a recommended action for the user to takebased at least in part on the response. The second device includes auser interface, a processor that includes a rule development moduleconfigured for developing the rule via the user interface, and acommunication port configured to communicate the rule to the firstdevice.

This summary is intended to provide an overview of the subject matter ofthe present patent application. It is not intended to provide anexclusive or exhaustive explanation of the invention. The detaileddescription is included to provide further information about the subjectmatter of the present patent application.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B illustrate portions of a device that includes an insulinpump.

FIG. 2 is a block diagram of an example of portions of an insulin pumpdevice.

FIG. 3 shows an example of a method for managing insulin therapy.

FIG. 4 shows a portion of an example of a decision tree to determine oneor more questions for the user of an insulin pump device.

FIG. 5 shows an example of a portion of a system that provides anenvironment to customize a rule for an insulin pump device.

DETAILED DESCRIPTION

The following detailed description includes references to theaccompanying drawings, which form a part of the detailed description.The drawings show, by way of illustration, specific embodiments in whichthe invention may be practiced. These embodiments, which are alsoreferred to herein as “examples,” are described in enough detail toenable those skilled in the art to practice the invention. Theembodiments may be combined, other embodiments may be utilized, orstructural, logical and electrical changes may be made without departingfrom the scope of the present invention. The following detaileddescription is, therefore, not to be taken in a limiting sense, and thescope of the present invention is defined by the appended claims andtheir equivalents.

In this document, the terms “a” or “an” are used, as is common in patentdocuments, to include one or more than one. In this document, the term“or” is used to refer to a nonexclusive or, such that “A or B” includes“A but not B,” “B but not A,” and “A and B,” unless otherwise indicated.Furthermore, all publications, patents, and patent documents referred toin this document are incorporated by reference herein in their entirety,as though individually incorporated by reference. In the event ofinconsistent usages between this document and those documents soincorporated by reference, the usage in the incorporated reference(s)should be considered supplementary to that of this document; forirreconcilable inconsistencies, the usage in this document controls.

FIGS. 1A and 1B illustrate portions of a device 100 that includes aninsulin pump. The device 100 includes a cassette or cartridge ofinsulin. The cartridge is connectable to infusion tubing 140 connectableto a patient such as by a Luer lock 145 or infusion set 142. The device100 includes a display 102 and a user interface that may include thedisplay 102 and include one or more keys 104. Because proper use of aninsulin pump requires a user to go through a learning curve to properlytreat their diabetes using the pump, it is desirable for a pump toprovide assistance to the user, whether the user is a diabetic patient,a caregiver, or a clinician. Providing an expert system in an insulinpump device will provide assistance to the user to effectively treattheir diabetes using the insulin pump device.

FIG. 2 is a block diagram of an example of portions of an insulin pumpdevice 200. The insulin pump device 200 includes a pump 205 or pumpmechanism to deliver insulin to a subject, such as a positivedisplacement pump for example. The insulin pump device 200 also includesa user interface 210, an input 215, and a controller 220. The userinterface 210 receives manual input from a user and may include one ormore pushbuttons or a keypad. The user interface 210 may include adisplay 202 to provide instructions to the user. The user of the devicemay be a clinician or a diabetic patient. The display 202 may include atouch-screen.

The input 215 is configured to receive blood glucose data of a patientor subject. The input 215 may be coupled to a blood glucose monitor (GM)included in the insulin pump device 200 or the input 215 may include acommunication port to receive the blood glucose data from a secondseparate device. In some embodiments, the communication port 235 is awireless communication port configured to receive the blood glucose datafrom the separate device wirelessly. If the GM is a continuous GM, thecontinuous GM automatically collects the sampled blood glucose data inreal time. The insulin pump device 200 may receive the blood glucose inreal time as it is obtained, or communicated at a later time. If thedata is communicated at a later time, a timestamp may be included withthe blood glucose data to indicate at what time the data was collected.In some embodiments, the input 215 is coupled to the user interface 210,and the user may manually input the data into the insulin pump device200 through a keypad included in the user interface 210.

In some examples, the GM may require a prompt from the user to begin ablood glucose data measurement to obtain the blood glucose data. Forexample, the GM may require diabetes test strips to take a blood glucosemeasurement. The controller 220 recurrently presents a prompt to theuser to begin a blood glucose measurement using the GM and obtain bloodglucose data. In certain examples, the prompt is presented periodically.The prompt may be presented via the display 202. The prompt may bepresented by activating a light emitting diode (LED) included in theinsulin pump device 200. In some examples, the prompt is presented byaudibly such as by a transducer or by a speaker instructing the user.The user then provides a new test strip to the GM when prompted duringthe correction factor test. In another example, the GM may include adrum of diabetes test strips and the user advances the drum to a freshor unused test strip when prompted by the controller 220.

If the insulin pump device 200 includes a continuous GM, the input 215may be coupled to blood glucose sensor circuit. The blood glucose sensorcircuit includes a blood glucose sensor to produce a blood glucosesignal representative of a blood glucose level of the patient. The bloodglucose sensor may sense blood glucose concentration from blood orinterstitial fluid. The blood glucose sensor circuit may include asensor interface circuit to sample the blood glucose signal and mayprovide additional signal processing such as filtering or amplificationfor example. The blood glucose sensor circuit may provide sampled bloodglucose data to the input 215. A description of a blood glucose sensorcircuit can be found in Steil et al., U.S. Pat. No. 6,558,351, filedJun. 1, 2000.

The controller 220 is operatively coupled to the pump mechanism 205, theinput 215, and the user interface 210. The controller 220 can beimplemented using hardware circuits, firmware, software or anycombination of hardware, firmware and software. Examples, include amicrocontroller, a logical state machine, and a processor such as amicroprocessor, application specific integrated circuit (ASIC), or othertype of processor. The controller 220 is configured to perform orexecute a function or functions. Such functions correspond to modules,which are software, hardware, firmware or any combination thereof.Multiple functions are performed in one or more modules.

The controller 220 monitors the blood glucose data of the subject. Thecontroller 220 includes a blood glucose data module 230. The bloodglucose data module 230 uses the blood glucose data to determine whethera blood glucose level of the subject is different from a target bloodglucose level. The target blood glucose level may include a specifiedrange of blood glucose levels and the blood glucose data module 230 maydetermine whether the blood glucose data indicates the blood glucose ofthe pump user is outside of a specified range of blood glucose levels.Being outside of a range may include having a blood glucose level thatis too high or too low. The blood glucose data module 230 may determinewhether a blood glucose level is above an acceptable range of higherblood glucose level, or below an acceptable range of low blood glucoselevels. The target or range may be stored in memory and be aprogrammable parameter available to the blood glucose data module 230. Aclinician would specify the range of blood glucose levels for thepatient. The range would depend on various factors for the patient suchas weight, age, and level of activity of the patient for example.

If the blood glucose data module 230 determines that the blood glucoselevel of the subject is different from the target or the specified rangeof blood glucose levels, the controller 220 presents one or morequestions related to the blood glucose level via the user interface 210.Preferably, the question is presented using the display 202. However, insome examples, the question may be presented audibly. Presenting thequestion audibly may be useful if the insulin pump user has difficultyseeing the display 202. The questions are designed to help a user toproperly treat their diabetes using the insulin pump device 200 and evenby programming the insulin pump device 200. In some examples, thecontroller 220 presents different questions according to different bloodglucose levels. For example, the controller 220 may present differentquestions according to whether the blood glucose level of the patient isabove 200 mg/dl, or above 300 mg/dl, or above 400 mg/dl. The clinicianmay program the different levels into the insulin pump device 200.

The user responds to the question through the user interface 210. Basedat least in part on one or more responses, the controller 220 displaysat least one recommended action for the user to take. As is discussedbelow, the recommended action may involve various user actions such astroubleshooting the insulin pump device 200, delivering insulin usingthe insulin pump device 200, initiating a measurement or test using theinsulin pump device 200, or making lifestyle changes for example. Insome examples, the recommended action for display may include contactinga physician. In some examples, the recommended action may be differentaccording to the blood glucose level of the patient. For example, thecontroller 220 may present different actions according to whether theblood glucose level of the patient is above 200 mg/dl, or above 300mg/dl, or above 400 mg/dl.

If the question is presented using a display 202, the device may includean alarm circuit 245 coupled to the controller 220 to draw the attentionof the user to the display 202. The alarm circuit 245 may include anaudible alarm, a visual indication such as a flashing light or flashingicon on the display, or the alarm circuit may mechanically vibrate theinsulin pump device to draw attention of the user. The controller 220activates the alarm circuit 245 if it is determined that the bloodglucose level of the subject is outside of the specified range of bloodglucose levels.

FIG. 3 shows an example of a method 300 for managing insulin therapy. Atblock 305, blood glucose data is received into an insulin pump device200. At block 310, at least one question related to a blood glucoselevel of a patient is presented when determining, from the blood glucosedata, that the blood glucose level is outside of a range of bloodglucose levels. The question may be presented on a display 202 includedwith the insulin pump device 200, or the question may be transmitted toa second device for display, such as a computer for example. This is maybe useful if a display 202 on the insulin pump device 200 is difficultfor the user to read. In some examples, the second device presents thequestion audibly. The insulin pump and the second device may communicatewirelessly such as by radio frequency (RF) or infrared red (IR)communication. At block 315, at least one response to the question isreceived into the insulin pump device 200. The response may be receivedthrough a user interface. At block 320, at least one recommended actionis presented for a user to take based, at least in part, on theresponse. The action may be presented audibly or visually, such as by adisplay for example.

Returning to FIG. 2, in some embodiments, the controller 220 includes arule module 225 to apply at least one rule to the blood glucose data todetermine the question to be presented. In some embodiments, the ruleincludes a decision tree. FIG. 4 shows a portion of an example of adecision tree 400 to determine one or more questions for the user of theinsulin pump device 200. In certain examples, the decision tree 400 mayimplemented with a series of IF-Then logic statements. The controller220 traverses the decision tree 400 using various information such asthe blood glucose data, responses from the user, or other data. If theblood glucose is high, the left portion of the decision tree 400 istraversed at block 405. The controller 220 may display a recommendedaction, such as the user taking a correction bolus at block 410, beforeasking one or more questions. If the blood glucose is low, the rightportion of the decision tree 400 is traversed at block 415. Thecontroller 220 may display a recommended action, such as the user eatingfood at block 420 before asking one or more questions. The controller220 may display a picture or icon of food when making therecommendation.

In some examples, the rule module 225 applies the rule to the bloodglucose data and to at least one user response to the question todetermine the recommended action for display. For example, using thedecision tree 400, if the blood glucose level is high, the controller220 may display a question asking if the infusion site is red at block425. If the user interface 210 receives a response from the user thatthe site is red, the controller 220 may display a recommendation thatthe user change the infusion site at block 430.

In some embodiments, the rule module 225 may include a look-up tablestored in a memory. For example, if the blood glucose is low, the lookup table may include a question as to whether the patient had a highactivity level. If the user interface 210 receives a response that theactivity level was high, the look up table includes a recommended actioncorresponding to a table entry for low blood glucose and high activity.The table entry may include a recommended action that the patient eatbefore the activity or lower a programmable basal rate of insulin beforeor during the activity. The table may include multiple dimensions totake into account multiple factors, responses, or other data. In someexamples, the rule module 225 assigns weights to corresponding tableentries. For example, receiving a response that the infusion set hasvisible blood may by weighted as a stronger indication to change theinfusion site than if a response is received that the infusion site isred. In some examples, the rule module 225 uses one or more fuzzy logicrules to determine the question for display and any recommended action.The fuzzy logic rules may be used to blend any weighted questions,responses, or actions. In some examples, the rule module 225 uses a ruleinvolving application of artificial intelligence methods to determinethe questions and the actions to be presented.

In some examples, the rule module 225 may apply the rule to the bloodglucose data and present a recommendation that the user initiate atleast one blood glucose measurement. The measurement may be made using asecond separate device that includes a GM, or the action may recommendmaking the measurement with the insulin pump device 200 if the deviceincludes a GM.

Note that application of the rule by the rule module 225 may result in aseries of questions displayed, responses by the user, and recommendactions. For example, the insulin pump device 200 may receive anindication that a recommended action was taken. The rule module 225 mayapply the rule to the blood glucose data, the response to the question,and the indication that the action was taken to determine at least oneof a further question and a further recommended action to be presented.

In some examples, the rule module 225 may apply the rule to the bloodglucose data and present a recommendation that the user initiate a basalrate test. Basal rate refers to a type of twenty-four hour backgroundinfusion of insulin by an insulin pump that mimics the continuousbackground release of insulin from a normal pancreas. It is the rate ofinsulin delivery the patient normally needs independent of theconsumption of meals. If the basal rate is inappropriate, blood glucoseconcentration levels may result that are out of a recommended or desiredrange. An insulin pump user may go through several iterations of trialand error before finding appropriate basal rates. Because a patient'sbasal insulin needs may change over time, such as with weight change orwith a change in fitness level, basal rate testing may be performedperiodically to ensure that an appropriate basal rate is being deliveredby an insulin pump. Based on the blood glucose level, the rule module225 determines that a recommendation to run a basal rate test (by eitherthe insulin pump device 200 or a separate device) should be presented(such as by display). As a result of the basal rate test, the controllermay display a recommendation to change a programmable basal rate patternor profile of the insulin pump device 200. Descriptions of devices andmethods that perform a basal rate test are found in Blomquist et al.,“Basal Rate Testing Using Frequent Blood Glucose Input,” U.S. patentapplication Ser. No. 11/685,617, filed Mar. 13, 2007, which isincorporated herein by reference.

In some examples, the rule module 225 may apply the rule to the bloodglucose data and present a recommendation that the user initiate acarbohydrate ratio test if the blood glucose level is outside a desiredrange. A carbohydrate ratio refers to the amount of carbohydratescovered by a unit of insulin. It is sometimes referred to as acarbohydrate factor, or carb factor, and is typically specified as gramsof carbohydrates per unit of insulin. The insulin pump device 200 mayuse the carbohydrate ratio to automatically determine a carbohydrateinsulin bolus amount required to match a number of carbohydratesingested by the patient, or at least to keep post-meal blood glucosewithin a range that is healthy for a patient. For example, the patientmay plan to eat seventy grams of carbohydrates. If the carbohydrateratio is ten grams of carbohydrates per unit of insulin, the insulinpump device 200 would determine that seven units of insulin are requiredto cover the carbohydrates.

The appropriate carbohydrate ratio may vary from person to person, yetit is important for an insulin pump to use an appropriate carbohydrateratio. If a carbohydrate ratio is too small, the pump may determine acarbohydrate bolus that is too large for the carbohydrates consumed.This may cause a low blood glucose level within a few hours of thecarbohydrate bolus (e.g., the blood glucose level drops below 70 mg/dl).If a carbohydrate bolus is too large, the insulin pump device 200 maydetermine a carbohydrate bolus that is too small for the carbohydratesconsumed. This may cause a high blood glucose level within a few hoursof a carbohydrate bolus. Based on the blood glucose level, the rulemodule 225 determines that a recommendation to run a carbohydrate ratiotest should be presented. As a result of the carbohydrate ratio test,the controller 220 may present a recommendation to change a carbohydrateinsulin bolus pattern or profile delivered by the insulin pump device200. For example, the controller 220 may recommend a carbohydrate boluspattern that includes an extended carbohydrate bolus or a combinationbolus. Descriptions of devices and methods that perform a carbohydrateratio test are found in Blomquist, “Carbohydrate Ratio Testing UsingFrequent Blood Glucose Input,” U.S. patent application Ser. No.11/679,712, filed Feb. 27, 2007, which is incorporated herein byreference.

In some examples, the rule module 225 may apply the rule to the bloodglucose data and present a recommendation that the user initiate acorrection factor test. A correction factor refers to the amount in dropin blood sugar, or blood glucose, for one unit of insulin. It ismeasured in milligrams per deciliter (mg/dl) per unit in the U.S. and inmillimoles (mmol) per unit in other countries. The insulin pump device200 may use the correction factor to automatically determine a bolusamount required for a high reading or a reduction in a meal bolus for abelow-target reading. The insulin pump device 200 may also use thecorrection factor to calculate the amount of carbohydrates a patientshould eat to bring low blood sugar up to a target blood sugar level. Anappropriate correction factor brings a high blood glucose reading downusing an automatically determined correction bolus without a risk ofgoing low.

The appropriate correction factor varies from person to person. It isimportant for an insulin pump to use an effective correction factor. Ifa correction factor for a pump is set too high, the blood glucose maynot actually be dropping as much as estimated and could lead to highblood glucose levels. If the correction factor is set too low, acorrection bolus may provide too much insulin and result in a low bloodglucose level. As a result of the carbohydrate ratio test, thecontroller 220 may display a recommendation to change an insulincorrection bolus pattern or profile, such as to include an extendedbolus or a combination bolus for example. Descriptions of devices andmethods that perform a carbohydrate ratio test are found in Blomquist etal., “Correction Factor Testing Using Frequent Blood Glucose Input,”U.S. patent application Ser. No. 11/626,653, filed Jan. 24, 2007, whichis incorporated herein by reference.

In some embodiments, the rule module 225 may receive an updated or newrule or a modification to the rule. In certain embodiments, the insulinpump device 200 includes a communication port 235 coupled to the input215. The communication port 235 receives the rule into the insulin pumpdevice 200 from a second separate device. In some examples, thecommunication port 235 is a wireless port and receives the rulewirelessly. The second device may be a computer or a personal dataassistant (PDA). The second device may provide an environment (e.g.,such as through software) for a diabetes professional, clinician, orother caregiver to customize the rule. In some examples, the environmentallows the clinician to customize a decision tree or look up table.

FIG. 5 shows an embodiment of a portion of a system 500 that provides anenvironment to customize rules in the rule module 225. The system 500includes an insulin pump device 200 and a computing device 550. Theinsulin pump device 200 includes a communication port 235 to communicateinformation with the computing device 550. The communication port 235shown is a wireless port that communicates wirelessly with the computingdevice 550, such as a radio frequency (RF) port or infrared (IR) portfor example. The communication port 235 may receive blood glucose datafrom a third device, such as a GM for example. In certain examples, theinsulin pump device 200 receives the blood glucose data from a GM whenthe GM is communicatively coupled to the communication port 235. Theinsulin pump device 200 is able to communicate information with thecomputing device 550 when the GM is not communicatively coupled to theinsulin pump device 200. In some examples, the communication port 235may be a wired port, such as a serial port for example, to communicatewith the computing device 550.

The computing device 550 may be a personal computer (PC), laptopcomputer, or a personal data assistant (PDA). The computing device 550includes a user interface 555 that includes a display and may include atleast one of a keyboard or keypad and a computer mouse. The computingdevice 550 also includes a processor 560 communicatively coupled to theuser interface 555. The processor 560 can be a microprocessor,application specific integrated circuit (ASIC), or other type ofprocessor.

The processor 560 includes a rule development module 565 that providesdoctors or clinical experts the ability to develop and generate a newrule or rule set or modify rules via the user interface 555. Thecomputing device 550 includes software that provides a flexibleframework to create or modify rules such as by updating a graphicaldecision tree, a multidimensional table, or other type of logical rule.The software may included in a computer readable medium, such as acompact disc (CD) for example, or the software may be downloaded to thecomputing device 550 from remote storage, such as from a server forexample. The rule development module 565 develops a rule to be appliedto the blood glucose data received into the insulin pump device 200, andmay develop a rule that is also applied to at least one of physiologicdata, demographic data, patient lifestyle data, insulin delivery historydata, and blood glucose history data to generate a recommended action.The computing device 550 includes a communication port 535 tocommunicate information with the insulin pump device 200. The computingdevice 550 uses the communication port 535 to communicate the rule tothe insulin pump device 200.

Once a rule is developed, the doctor or clinical expert could publish orotherwise share a rule or set of rules. In some embodiments, rule setscan be stored in remote storage, such as a server for example. Thecomputing device 550 may be connected to a communication network, suchas the internet or a cell phone network for example. A doctor orclinical expert may download a rule or rule set from the remote storageand either download the rule set directly from the computing device 550into the insulin pump device 200 or modify the rule or rule set beforedownloading the modified rule or rule set to the insulin pump device200.

Returning to FIG. 2, in some embodiments, the user interface 210 and theinput 215 receive modifications to the rule that are entered into theinsulin pump device 200 manually by the user via the user interface 210.For example, the user may step through the rule with the aid of thedisplay 202. The user may then alter the rule with a keypad included inthe user interface 210. For example, the user may enter a new look uptable entry using the key pad, or add another branch to a decision treeor edit a branch of the decision tree. In certain embodiments, an entirenew rule or rule set is entered manually into the insulin pump device200 via the user interface 210.

In some embodiments, the insulin pump device 200 stores data to trackeffectiveness of a new rule or modified rule. For example, the insulinpump device 200 may track the number of times the blood glucose level ofthe patient returned to the target blood glucose level or to within thetarget range of levels after application of the rule. The effectivenessmay be displayed as a percentage or as X successes out of Y applicationson either a display 202 of the insulin pump or uploaded and displayed ona separate device, such as the computing device 550 in FIG. 5 forexample.

If a rule or rule set is downloaded into multiple devices, theeffectiveness of the rule set for multiple device may be tracked. Thestored data related to the effectiveness may be uploaded to a remoteserver and the server tracks the overall effectiveness of the rule overthe multiple devices. The overall effectiveness may be useful to aclinician in determining whether to download a particular rule or ruleset to the insulin pump device 200.

In some embodiments, controller 220 determines a rate of change of ablood glucose level of the subject from the blood glucose data. Forexample, the controller 220 may determine that the blood glucoseconcentration level is increasing or decreasing at a rate of 2 to 4mg/dl/min (milligrams per deciliter per minute). The rule module 225 mayapply one or more rules to the rate of change of a blood glucose levelto determine at least one of a question for display or one or morerecommended actions for display. For example, the blood glucose level ofthe user may not be high, but the rate of change of blood glucose may beincreasing at such a rate to indicate there is a risk of the bloodglucose level going high. Conversely, the blood glucose level of theuser may not be below a blood glucose target, but the rate of change ofblood glucose may be decreasing at such a rate to indicate there is arisk of the blood glucose level going low.

In some examples, the rule module 225 may apply the rules to at leastone of the blood glucose data, the rate of change of blood glucose data,and a response to a question to determine a subsequent question orrecommended action for display by the controller 220. For example, ifthe blood glucose level is high and increasing at a certain rate, therule module 225 may apply the rule to determine that a recommendedaction to take a correction bolus should be presented before presentinga question. In another example, if the blood glucose level is high anddecreasing at a certain rate, the rule module 225 may apply the rule todetermine that a recommended action to take a correction bolus shouldnot be displayed and proceed to displaying a question such as whetherthe patient ate something where it was difficult to estimate thecarbohydrates.

According to some embodiments, the controller 220 may display arecommendation that the patient consume carbohydrates if the bloodglucose level is low or there is a risk of blood glucose level goinglow. In some examples, the memory 240 may store a database of foodoptions in association with a known amount of carbohydrates. Therecommended action presented by the controller 220 may includedisplaying a food option for consumption that is included in thedatabase.

In some embodiments, the controller 220 determines an amount ofcarbohydrates for the patient to consume and presents a food optionaccordingly. For example, assume that the blood glucose level of apatient is 40 mg/dl below a desired range of blood glucose levels. Thecorrection factor is stored in the insulin pump device 200 and is 1 unitper 80 mg/dl. The controller 220 determines that −0.5unit of insulin(−40/80) is required to bring the blood glucose level back to the targetlevel or range. Further assume that the carbohydrate ratio of thepatient is 20 grams of carbohydrates per unit of insulin (20 g/u). Thecontroller 220 multiplies the amount of insulin by the carbohydrateratio to determine that the patient should eat 10 grams of carbohydrates[(0.5)(20)]. The insulin calculation module 125 may take into accountadditional factors such as the health status of the patient and theactivity level of the patient in recommending the carbohydrate amount.In some example, the food option may be displayed using an icon orpicture of food.

According to some embodiments, the input 215 receives physiologic datainto the insulin pump device 200 from a separate second device. The datamay be received through the input 215 or another input. In someembodiments, the insulin pump device 200 receives the physiologic datathrough a communication port 235. In some examples, the insulin pumpdevice 200 receives the physiologic data through the same communicationport 235 that receives the blood glucose data. In some examples, thesecond device includes a temperature monitor and the physiologic dataincludes a patient temperature. In some examples, the second deviceincludes an activity monitor and the physiologic data includes anindication of a level of patient activity.

The rule module 225 may apply one or more rules to the physiologic datato determine a question for display. The rule module 225 may apply oneor more rules to the physiologic data and a response to the question todetermine one or more recommended actions for display. In some examples,the rule module 225 may apply one or more rules to the physiologic data,the blood glucose data, at least one question response to determine aquestion or recommended action for display. The controller 220 displaysthe questions and recommended actions.

In some embodiments, the insulin pump device 200 includes a memory 240communicatively coupled to the controller 220. The memory 240 may storedemographic data of the subject. The demographic data includes suchinformation as a patient's weight, age, and gender for example. Thedemographic data may be received from a second device or through theuser interface 210. The rule module 225 may apply one or more rules tothe demographic data to determine a question to be presented. The rulemodule 225 may apply one or more rules to the demographic data and aresponse to the question to determine and/or adjust one or morerecommended actions. In some examples, the rule module 225 may apply oneor more rules to the demographic data, the blood glucose data, at leastone question response to determine a question or recommended action fordisplay.

In some embodiments, the controller 220 adjusts the questions andrecommended actions based on the demographic data. For example, thecontroller 220 may use a different set of questions and recommendedactions when the demographic data indicates that the patient is a childthan when the demographic data indicates the patient is an adult.

In some embodiments, the memory 240 may store lifestyle data of thesubject. The lifestyle data includes such information as whether apatient tends to eat high glycemic index foods, drinks alcohol, smokes,eats a bedtime snack, a health status of the patient, whether thepatient is typically under stress, whether the patient tends to beactive, and the amount time he patient spends exercising, for example.The lifestyle data may be received from a second device or enteredthrough the user interface 210. The rule module 225 may apply one ormore rules to the lifestyle data to determine a question for display.The rule module 225 may apply one or more rules to the lifestyle dataand a response to the question to determine one or more recommendedactions for display. In some examples, the rule module 225 may apply oneor more rules to the lifestyle data, the blood glucose data, at leastone question response to determine a question or recommended action fordisplay.

A recommended action may include a change to at least one aspect of thepatient's lifestyle, such as to skip the bedtime snack or to eat lowerglycemic index meals, for example. In some examples, the recommendedaction may include recommending patient training In certain examples,the insulin pump device 200 may present a recommendation that thepatient be trained in carbohydrate counting. In certain examples, theinsulin pump device 200 may recommend that the patient be trained inmanaging their exercise. In certain examples, the insulin pump device200 may recommend that the patient be trained in using the insulin pumpwhen the patient is sick. In certain examples, the insulin pump device200 may recommend that the patient be trained in proper infusion sitecare.

In some embodiments, the memory 240 may store insulin delivery historydata of the patient. Insulin delivery history data may include a timeduration since the last meal bolus, how long since the cartridge waschanged, and whether there have been any recent changes to programmingparameters and what those changes were for example. The rule module 225may apply one or more rules to the insulin delivery history data todetermine a question to be presented. The rule module 225 may apply oneor more rules to at least one of the insulin delivery history data, theblood glucose data, and a response to a question to determine one ormore recommended actions.

In some embodiments, the memory 240 may store blood glucose history dataof the subject. Blood glucose history data may include blood glucosedata from a previous time period, such as two hours or 24 hours in thepast for example. The data may be received from a GM included in theinsulin pump device 200 or from a GM included in a separate device. Insome examples, the blood glucose history data may be received from aseparate computing device such as a PC, laptop, or PDA configured tocommunicate with the insulin pump device 200. The controller 220 maygenerate a prompt to download blood glucose history data from the secondseparate device, such as a prompt on a display 202, an LED prompt, or anaudible prompt. The rule module 225 may apply one or more rules to theblood glucose history data to determine a question to be presented. Therule module 225 may apply one or more rules to at least one of the bloodglucose history data, the blood glucose data collected in real time, anda response to a question to determine one or more recommended actions.

The patient may experience trouble with the insulin pump device 200itself. According to some embodiments, the recommended action presentedby the controller 220 includes actions for troubleshooting the insulinpump device 200. If the blood glucose level is low, the recommendedactions may include checking or changing the insulin cartridge, theinfusion set, the infusion set tubing, and/or the infusion site. Forexample, if the insulin pump device 200 stores the time since thecartridge was changed, the rule module 225 may determine that it is timefor a new cartridge and display instructions to check whether thecartridge is low or change the cartridge. If it has been a short timesince the cartridge was changed, the rule module 225 may eliminate thecartridge as the problem and display instructions to check or change theinfusion set or the infusion site.

In another example, the user may respond that the cartridge was checked.The rule module 225 may apply the rule to the blood glucose level andthe response and eliminate the cartridge as the problem. The insulinpump device 200 and the user may then step through response and actionsthat instruct the user to troubleshoot the infusion set and site. Thecontroller 220 may also present a recommendation to change the type ofinsulin. For example, the rule module 225 may determine that the delayfor uptake is too slow and recommend that the patient use a type ofinsulin with faster uptake. The controller 220 may also present arecommendation to change an insulin pump executable program and to see adiabetes professional. The controller may present a question whether theinfusion set has visible blood and recommend that the infusion site bechanged if there is visible blood. In some examples, the controller 220may display a device error code and a recommendation to see the diabetesprofessional rather than present instructions to the user or patientthat the pump program should be changed. The diabetes professionalinterprets the error code to determine the recommended action.

According to some examples, the blood glucose data module 230 maydetermine from the blood glucose data that a blood glucose level of thesubject is at a target blood glucose level or within a specified rangeof blood glucose levels. The rule module 225 may determine one or morerecommend actions for the patient to take that are related tomaintaining normoglycemia. The rule module 225 may apply the rule to theblood glucose data and at least one of the physiologic data, thedemographic data, the lifestyle data, the blood glucose history data,the insulin delivery history data, question responses, and previousactions taken to make the recommendation. The controller 220 displaysthe recommended action. For example, the controller 220 may asklifestyle questions when blood glucose data is in the normoglycemicrange. The controller 220 may aggregate insulin pump data and answers tothe questions from various times when the blood glucose data values werein range and help the patient identify lifestyle or therapy patternsthat promote good glycemic control.

It is to be understood that the above description is intended to beillustrative, and not restrictive. For example, the above-describedembodiments (and/or aspects thereof) may be used in combination witheach other. Many other embodiments will be apparent to those of skill inthe art upon reviewing the above description. The scope of the inventionshould, therefore, be determined with reference to the appended claims,along with the full scope of equivalents to which such claims areentitled. In the appended claims, the terms “including” and “in which”are used as the plain-English equivalents of the respective terms“comprising” and “wherein.” Also, in the following claims, the terms“including” and “comprising” are open-ended, that is, a system, device,article, or process that includes elements in addition to those listedafter such a term in a claim are still deemed to fall within the scopeof that claim. Moreover, in the following claims, the terms “first,”“second,” and “third,” etc. are used merely as labels, and are notintended to impose numerical requirements on their objects.

The Abstract of the Disclosure is provided to comply with 37 C.F.R.§1.72(b), requiring an abstract that will allow the reader to quicklyascertain the nature of the technical disclosure. It is submitted withthe understanding that it will not be used to interpret or limit thescope or meaning of the claims. In addition, in the foregoing DetailedDescription, it can be seen that various features are grouped togetherin a single embodiment for the purpose of streamlining the disclosure.This method of disclosure is not to be interpreted as reflecting anintention that the claimed embodiments require more features than areexpressly recited in each claim. Rather, as the following claimsreflect, inventive subject matter lies in less than all features of asingle disclosed embodiment. Thus the following claims are herebyincorporated into the Detailed Description, with each claim standing onits own.

1-20. (canceled)
 21. A method comprising: receiving sensor glucose datafrom a continuous glucose monitor at a device that includes an insulinpump via a wireless connection; monitoring the sensor glucose data witha controller of the device; determining with the controller, from thesensor glucose data, that a sensor glucose level of a user is below alow glucose limit; alerting the user that the sensor glucose level isbelow the low glucose limit; and displaying to the user on a display ofthe device a recommendation for the user to initiate a blood glucosemeasurement with a glucose meter.
 22. The method of claim 21, whereinalerting the user that the sensor glucose level is below the low glucoselimit includes activating an alarm.
 23. The method of claim 22, whereinthe alarm is selected from one or more of the group consisting of: anaudible alarm, a visual alarm, and a vibratory alarm.
 24. The method ofclaim 21, further comprising storing in memory of the device a low bloodglucose limit programmed by the user.
 25. The method of claim 21,further comprising automatically suspending an operation being carriedout by the device upon determining that the sensor glucose level of theuser is below the low glucose limit.
 26. The method of claim 25, whereinthe operation being carried out by the device relates to basal deliveryof insulin with the device.
 27. The method of claim 26, wherein theoperation relating to basal delivery of insulin is a basal rate test fordetermining a basal rate for delivery of insulin to the user to maintaina blood glucose level of the user within a target range.
 28. The methodof claim 21, further comprising: prompting the user for a responserelating to the sensor glucose level; and operating the device based atleast in part on the user response.
 29. A system comprising: a pumpconfigured to deliver insulin; an input configured to receive sensorglucose data from a continuous glucose monitor via a wirelessconnection; a user interface; and a controller communicatively coupledto the pump, the input, and the user interface, the controller includinga blood glucose data module configured to compare the sensor glucosedata to a low glucose limit for a user, and wherein the controller isconfigured to: determine from the sensor glucose data that a sensorglucose level of the user is below the low glucose limit for the user;alert the user that the sensor glucose level is below the low glucoselimit; and display to the user on the user interface a recommendationfor the user to initiation a blood glucose measurement with a glucosemeter.
 30. The system of claim 29, wherein the controller is furtherconfigured to alert the user that the sensor glucose level is below thelow glucose limit by activating an alarm.
 31. The system of claim 30,wherein the alarm is selected from one or more of the group consistingof: an audible alarm, a visual alarm, and a vibratory alarm.
 32. Thesystem of claim 29, further comprising a memory communicatively coupledto the controller and wherein the controller is further configured tostore in the memory of a low blood glucose limit programmed by the user.33. The system of claim 29, wherein the controller is further configuredto automatically suspend an operation being carried out by the pump upondetermining that the sensor glucose level of the user is below the lowglucose limit.
 34. The system of claim 33, wherein the operation beingcarried out by the pump relates to basal delivery of insulin with thepump.
 35. The system of claim 34, wherein the operation relating tobasal delivery of insulin is a basal rate test for determining a basalrate for delivery of insulin to the user to maintain a blood glucoselevel of the user within a target range.
 36. The system of claim 29,wherein the controller is configured to: prompt the user for a responserelating to the sensor glucose level; and operate the pump based atleast in part on the user response.
 37. The system of claim 29, furthercomprising a continuous glucose monitoring sensor.